MA48448A - Dérivés de quinazoline utilisés pour traiter le vih - Google Patents

Dérivés de quinazoline utilisés pour traiter le vih

Info

Publication number: MA48448A
Authority: MA; Morocco
Prior art keywords: derivatives used; quinazoline derivatives; treat hiv; hiv; treat
Prior art date: 2014-12-24

Application number

MA048448A

Other languages

English (en)

Inventor

Ondrej Baszczynski

Milan Dejmek

Yunfeng Eric Hu

Petr Jansa

Eric Lansdon

Richard L Mackman

Petr Simon

Original Assignee

Gilead Sciences Inc

Inst Of Organic Chemistry And Biochemistry As Cr V V I

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-24

Filing date

2015-12-23

Publication date

2021-04-28

2015-12-23 Application filed by Gilead Sciences Inc, Inst Of Organic Chemistry And Biochemistry As Cr V V I filed Critical Gilead Sciences Inc

2021-04-28 Publication of MA48448A publication Critical patent/MA48448A/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA048448A 2014-12-24 2015-12-23 Dérivés de quinazoline utilisés pour traiter le vih MA48448A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201462096748P	2014-12-24	2014-12-24

Publications (1)

Publication Number	Publication Date
MA48448A true MA48448A (fr)	2021-04-28

Family

ID=55305044

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA048448A MA48448A (fr)	2014-12-24	2015-12-23	Dérivés de quinazoline utilisés pour traiter le vih

Country Status (41)

Country	Link
US (5)	US9730936B2 (fr)
EP (4)	EP3521282B1 (fr)
JP (2)	JP6367489B2 (fr)
KR (2)	KR102049476B1 (fr)
CN (2)	CN107278201B (fr)
AR (1)	AR103252A1 (fr)
AU (1)	AU2015371198B2 (fr)
BR (1)	BR102015032361B1 (fr)
CA (1)	CA2972021C (fr)
CL (1)	CL2017001675A1 (fr)
CO (1)	CO2017006214A2 (fr)
CR (1)	CR20170281A (fr)
CU (1)	CU20170089A7 (fr)
CY (1)	CY1124726T1 (fr)
DK (1)	DK3521282T3 (fr)
DO (1)	DOP2017000151A (fr)
EA (2)	EA035746B1 (fr)
EC (1)	ECSP17039611A (fr)
ES (3)	ES2964395T3 (fr)
HK (1)	HK1244001B (fr)
HR (1)	HRP20211543T1 (fr)
HU (1)	HUE058296T2 (fr)
IL (2)	IL253059B (fr)
LT (1)	LT3521282T (fr)
MA (1)	MA48448A (fr)
MD (1)	MD4650B1 (fr)
MX (2)	MX367574B (fr)
MY (1)	MY189761A (fr)
NZ (1)	NZ733174A (fr)
PE (1)	PE20171306A1 (fr)
PH (1)	PH12017501191B1 (fr)
PL (3)	PL3237398T3 (fr)
PT (2)	PT3237398T (fr)
SA (1)	SA517381826B1 (fr)
SG (2)	SG11201705215PA (fr)
SI (2)	SI3237398T1 (fr)
SV (1)	SV2017005471A (fr)
TR (1)	TR201903672T4 (fr)
TW (3)	TW202237569A (fr)
UA (1)	UA117796C2 (fr)
WO (1)	WO2016105564A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2553449T3 (es)	2011-07-06	2015-12-09	Gilead Sciences, Inc.	Compuestos para el tratamiento de VIH
EP3237397B1 (fr)	2014-12-24	2018-11-21	Gilead Sciences, Inc.	Composés isoindoline pour le traitement du vih
ES2735087T3 (es)	2014-12-24	2019-12-16	Gilead Sciences Inc	Compuestos de pirimidina fusionados para el tratamiento de VIH
TW202237569A (zh) *	2014-12-24	2022-10-01	美商基利科學股份有限公司	喹唑啉化合物
US20190022116A1 (en)	2014-12-26	2019-01-24	Emory University	N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
TWI808055B (zh)	2016-05-11	2023-07-11	美商滬亞生物國際有限公司	Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh)	2016-05-11	2023-03-01	美商滬亞生物國際有限公司	Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN111793061A (zh)	2016-08-19	2020-10-20	吉利德科学公司	用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
AR112412A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
AR112413A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas sólidas de un inhibidor de la cápside del vih
WO2019113462A1 (fr)	2017-12-07	2019-06-13	Emory University	N4-hydroxycytidine et dérivés et leurs utilisations anti-virales
KR102587510B1 (ko)	2018-02-15	2023-10-11	길리애드 사이언시즈, 인코포레이티드	피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
EP3752496B1 (fr)	2018-02-16	2023-07-05	Gilead Sciences, Inc.	Procédés et intermédiaires pour préparer un composé thérapeutique utile dans le traitement d'une infection virale par retroviridae
EP3823621A1 (fr)	2018-07-16	2021-05-26	Gilead Sciences, Inc.	Inhibiteurs de capsides pour le traitement du vih
TW202104210A (zh)	2019-04-17	2021-02-01	美商基利科學股份有限公司	Hiv蛋白酶抑制劑
WO2020214647A1 (fr)	2019-04-17	2020-10-22	Gilead Sciences, Inc.	Formes solides d'un inhibiteur de protéase du vih
CA3157275A1 (fr)	2019-11-26	2021-06-03	Elena BEKERMAN	Inhibiteurs de capside pour la prevention du vih
AR121620A1 (es)	2020-03-20	2022-06-22	Gilead Sciences Inc	Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos
KR20230005827A (ko)	2020-04-24	2023-01-10	스미토모 파마 가부시키가이샤	2-헤테로아릴아미노퀴나졸리논 유도체
CN115996925A (zh)	2020-06-25	2023-04-21	吉利德科学公司	用于治疗hiv的衣壳抑制剂
AU2021377614A1 (en)	2020-11-11	2023-06-22	Gilead Sciences, Inc.	METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
TW202342448A (zh)	2021-12-03	2023-11-01	美商基利科學股份有限公司	用於ｈｉｖ病毒感染之治療性化合物
TW202342447A (zh)	2021-12-03	2023-11-01	美商基利科學股份有限公司	用於ｈｉｖ病毒感染之治療性化合物
EP4440702A1 (fr)	2021-12-03	2024-10-09	Gilead Sciences, Inc.	Composés thérapeutiques contre l'infection par le virus du vih
TWI843506B (zh)	2022-04-06	2024-05-21	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202402280A (zh)	2022-07-01	2024-01-16	美商基利科學股份有限公司	可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
WO2024044477A1 (fr)	2022-08-26	2024-02-29	Gilead Sciences, Inc.	Régime de dosage et de planification pour anticorps largement neutralisants
WO2024076915A1 (fr)	2022-10-04	2024-04-11	Gilead Sciences, Inc.	Analogues de 4'-thionucléosides et leur utilisation pharmaceutique
WO2024220624A1 (fr)	2023-04-19	2024-10-24	Gilead Sciences, Inc.	Schéma posologique d'inhibiteur de capside

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ197420A (en)	1980-07-01	1984-04-27	Ici Australia Ltd	-(quinazolin-(2-or 4-)(oxy,ylthio or amino)phen(oxy or ylthio)alkanoic acid derivatives
JPH11209350A (ja)	1998-01-26	1999-08-03	Eisai Co Ltd	含窒素複素環誘導体およびその医薬
WO2001021598A1 (fr)	1999-09-23	2001-03-29	Astrazeneca Ab	Composes therapeutiques de quinazoline
JP2003514901A (ja)	1999-11-22	2003-04-22	ワーナー−ランバート・カンパニー	キナゾリン類およびシクリン依存性キナーゼ酵素を阻害するためのその使用
GB0002032D0 (en)	2000-01-28	2000-03-22	Zeneca Ltd	Chemical compounds
WO2002010136A1 (fr)	2000-08-02	2002-02-07	Celltech R & D Limited	Derives d'isoquinoline-1-yl substitues en 3
CA2422488A1 (fr)	2000-09-20	2002-03-28	Merck Patent Gesellschaft Mit Beschraenkter Haftung	4-amino-quinazolines
WO2004030672A1 (fr)	2002-10-02	2004-04-15	Merck Patent Gmbh	Utilisation de 4 amino-quinazolines comme agents anticancereux
SG182849A1 (en)	2003-04-25	2012-08-30	Gilead Sciences Inc	Antiviral phosphonate analogs
WO2004108711A1 (fr)	2003-06-05	2004-12-16	Astrazeneca Ab	Derives pyrazinile quinazoline destines au traitement de tumeurs
JP2007008816A (ja)	2003-10-15	2007-01-18	Ube Ind Ltd	新規イソキノリン誘導体
US7871991B2 (en)	2004-07-27	2011-01-18	Gilead Sciences, Inc.	Phosphonate analogs of HIV inhibitor compounds
US20070054916A1 (en)	2004-10-01	2007-03-08	Amgen Inc.	Aryl nitrogen-containing bicyclic compounds and methods of use
MX2007005159A (es)	2004-10-29	2007-06-26	Tibotec Pharm Ltd	Derivados de pirimidina biciclicos inhibidores del vih.
EP1844023A1 (fr)	2004-12-31	2007-10-17	Sk Chemicals Co., Ltd.	Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité
WO2006099301A2 (fr)	2005-03-10	2006-09-21	The Regents Of The University Of California	Inhibiteurs de l'apoptose
EP1878727A4 (fr)	2005-04-28	2013-11-13	Kyowa Hakko Kirin Co Ltd	Dérivés de 2-aminoquinazoline
BRPI0613597A2 (pt)	2005-06-28	2011-01-18	Sanofi Aventis	derivado de isoquinolina como inibidores de rho-quinase
ES2423006T3 (es)	2005-07-26	2013-09-17	Sanofi	Derivados de isoquinolona sustituidos con piperidinilo como inhibidores de la cinasa Rho
US7989461B2 (en)	2005-12-23	2011-08-02	Amgen Inc.	Substituted quinazolinamine compounds for the treatment of cancer
AU2007211077B2 (en)	2006-01-27	2012-09-20	Fibrogen, Inc.	Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (HIF)
TW200808739A (en)	2006-04-06	2008-02-16	Novartis Vaccines & Diagnostic	Quinazolines for PDK1 inhibition
WO2007125405A2 (fr)	2006-05-01	2007-11-08	Pfizer Products Inc.	Composés hétérocycliques 2-amino-substitués à cycles fusionnés
ATE469144T1 (de)	2006-07-20	2010-06-15	Amgen Inc	Substituierte pyridonverbindungen und anwendungsverfahren
US8027888B2 (en)	2006-08-31	2011-09-27	Experian Interactive Innovation Center, Llc	Online credit card prescreen systems and methods
JPWO2008050808A1 (ja)	2006-10-24	2010-02-25	協和発酵キリン株式会社	２−アミノキナゾリン誘導体
BRPI0720862A2 (pt)	2006-12-27	2014-02-25	Sanofi Aventis	Derivados de isoquinolina e isoquinolinona substituídos como inibidores de rho-cinase
BRPI0720710A2 (pt)	2006-12-27	2014-12-23	Sanofi Aventis	Derivados de isoquinolona e isoquinolinona substituídos com cicloalquilamina
EP2125745B1 (fr)	2006-12-27	2017-02-22	Sanofi	Dérivés d'isoquinolone substitués par une cycloalkylamine
US20090004185A1 (en)	2007-01-11	2009-01-01	Wyeth	Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents
MX2009010696A (es)	2007-04-06	2009-10-20	Novartis Ag	Derivados de 2,6-naftiridina como moduladores de cinasa de proteina.
US20090209536A1 (en)	2007-06-17	2009-08-20	Kalypsys, Inc.	Aminoquinazoline cannabinoid receptor modulators for treatment of disease
CA2707418C (fr)	2007-11-16	2013-11-19	Boehringer Ingelheim International Gmbh	Inhibiteurs de la replication du virus de l'immunodeficience humaine
WO2009131173A1 (fr)	2008-04-23	2009-10-29	協和発酵キリン株式会社	Dérivé de 2-aminoquinazoline
MX315904B (es)	2008-05-30	2013-11-29	Amgen Inc	Inhibidores de fosfoinosituro-3 cinasa.
GB0812969D0 (en)	2008-07-15	2008-08-20	Sentinel Oncology Ltd	Pharmaceutical compounds
US8573519B2 (en)	2008-08-15	2013-11-05	Basf Se	Process for producing nanoscale organic solid particles
ES2467108T3 (es)	2008-12-09	2014-06-11	Gilead Sciences, Inc.	Moduladores de receptores tipo toll
MX2011007064A (es)	2008-12-29	2012-01-20	Fovea Pharmaceuticals	Compuestos de quinazolina substituidos.
EP2416660B1 (fr)	2009-04-07	2014-07-02	Infinity Pharmaceuticals, Inc.	Inhibiteurs d'amide d'hydrolase d'acide gras
US8338441B2 (en)	2009-05-15	2012-12-25	Gilead Sciences, Inc.	Inhibitors of human immunodeficiency virus replication
WO2011035416A1 (fr)	2009-09-25	2011-03-31	Aegera Therapeutics Inc.	Composés modulateurs de la hsp90, compositions, procédés et utilisations correspondants
WO2011139637A1 (fr)	2010-05-03	2011-11-10	Philadelphia Health & Education Corporation	Modulateurs à petite molécule de stabilité de capside de vih-1 et procédés pour ceux-ci
TW201210597A (en)	2010-06-09	2012-03-16	Gilead Sciences Inc	Inhibitors of hepatitis C virus
TW201204723A (en)	2010-06-22	2012-02-01	Fovea Pharmaceuticals	Heterocyclic compounds, their preparation and their therapeutic application
US9102617B2 (en)	2010-06-25	2015-08-11	Rutgers, The State University Of New Jersey	Antimicrobial agents
AP2013006707A0 (en)	2010-07-02	2013-02-28	Gilead Sciences Inc	2-Quinolinyl-acetic acid derivatives as HIV antiviral compounds
CA2802308C (fr)	2010-07-02	2018-08-28	Lianhong Xu	Derives d'acide napht-2-ylacetique dans le traitement du sida
KR20130141500A (ko)	2010-09-29	2013-12-26	크리스탈지노믹스(주)	단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
KR20120038060A (ko)	2010-10-13	2012-04-23	롬엔드하스전자재료코리아유한회사	신규한 유기 전자재료용 화합물 및 이를 포함하는 유기 전계 발광 소자
JP6026427B2 (ja)	2010-12-17	2016-11-16	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	置換６，６−縮合窒素複素環化合物及びその使用
WO2012116237A2 (fr)	2011-02-23	2012-08-30	Intellikine, Llc	Composés hétérocycliques et leurs utilisations
KR20140027295A (ko)	2011-04-21	2014-03-06	길리애드 사이언시즈, 인코포레이티드	벤조티아졸 화합물 및 이들의 약학적 용도
ES2553449T3 (es)	2011-07-06	2015-12-09	Gilead Sciences, Inc.	Compuestos para el tratamiento de VIH
CN102863512B (zh)	2011-07-07	2016-04-20	上海泓博智源医药技术有限公司	抗病毒化合物
WO2013091096A1 (fr)	2011-12-20	2013-06-27	Boehringer Ingelheim International Gmbh	Composés tricycliques condensés en tant qu'inhibiteurs de la réplication du vih
CN105121418A (zh)	2012-04-20	2015-12-02	吉利德科学公司	苯并噻唑-6-基乙酸衍生物及其治疗hiv感染的用途
SI3608325T1 (sl)	2012-12-21	2022-09-30	Gilead Sciences, Inc.	Policiklične-karbamoilpiridonske spojine in njihova farmacevtska uporaba
RU2015131006A (ru)	2012-12-27	2017-01-30	Джапан Тобакко Инк.	ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ)
EP2769722A1 (fr)	2013-02-22	2014-08-27	Ruprecht-Karls-Universität Heidelberg	Composés utilisés pour inhiber un assemblage de capside du VIH
EP2769723A1 (fr)	2013-02-22	2014-08-27	Ruprecht-Karls-Universität Heidelberg	Composés utilisés pour inhiber un assemblage de capside du VIH
US9914709B2 (en)	2013-06-21	2018-03-13	Yale University	Compositions and methods of treating HIV-1 infections using same
EP3237397B1 (fr)	2014-12-24	2018-11-21	Gilead Sciences, Inc.	Composés isoindoline pour le traitement du vih
ES2735087T3 (es)	2014-12-24	2019-12-16	Gilead Sciences Inc	Compuestos de pirimidina fusionados para el tratamiento de VIH
TW202237569A (zh)	2014-12-24	2022-10-01	美商基利科學股份有限公司	喹唑啉化合物

2015
- 2015-12-18 TW TW111121406A patent/TW202237569A/zh unknown
- 2015-12-18 TW TW104142712A patent/TWI699355B/zh active
- 2015-12-18 TW TW109122699A patent/TWI770552B/zh active
- 2015-12-22 AR ARP150104262A patent/AR103252A1/es unknown
- 2015-12-23 PL PL15832711T patent/PL3237398T3/pl unknown
- 2015-12-23 EP EP18213309.0A patent/EP3521282B1/fr active Active
- 2015-12-23 EP EP15832711.4A patent/EP3237398B1/fr active Active
- 2015-12-23 MX MX2017008521A patent/MX367574B/es active IP Right Grant
- 2015-12-23 WO PCT/US2015/000460 patent/WO2016105564A1/fr active Application Filing
- 2015-12-23 PL PL18213309T patent/PL3521282T3/pl unknown
- 2015-12-23 CN CN201580076616.XA patent/CN107278201B/zh active Active
- 2015-12-23 ES ES21187414T patent/ES2964395T3/es active Active
- 2015-12-23 HR HRP20211543TT patent/HRP20211543T1/hr unknown
- 2015-12-23 SI SI201530560T patent/SI3237398T1/sl unknown
- 2015-12-23 EP EP23196262.2A patent/EP4302830A3/fr active Pending
- 2015-12-23 CR CR20170281A patent/CR20170281A/es unknown
- 2015-12-23 PT PT15832711T patent/PT3237398T/pt unknown
- 2015-12-23 EA EA201791256A patent/EA035746B1/ru unknown
- 2015-12-23 LT LTEP18213309.0T patent/LT3521282T/lt unknown
- 2015-12-23 SG SG11201705215PA patent/SG11201705215PA/en unknown
- 2015-12-23 NZ NZ733174A patent/NZ733174A/en unknown
- 2015-12-23 SG SG10202101143VA patent/SG10202101143VA/en unknown
- 2015-12-23 PE PE2017001139A patent/PE20171306A1/es unknown
- 2015-12-23 ES ES18213309T patent/ES2900810T3/es active Active
- 2015-12-23 PL PL21187414.4T patent/PL3960735T3/pl unknown
- 2015-12-23 EP EP21187414.4A patent/EP3960735B1/fr active Active
- 2015-12-23 DK DK18213309.0T patent/DK3521282T3/da active
- 2015-12-23 JP JP2017534259A patent/JP6367489B2/ja active Active
- 2015-12-23 KR KR1020177020449A patent/KR102049476B1/ko active IP Right Grant
- 2015-12-23 AU AU2015371198A patent/AU2015371198B2/en active Active
- 2015-12-23 PT PT182133090T patent/PT3521282T/pt unknown
- 2015-12-23 MD MDA20170070A patent/MD4650B1/ro not_active IP Right Cessation
- 2015-12-23 CU CUP2017000089A patent/CU20170089A7/es unknown
- 2015-12-23 HU HUE18213309A patent/HUE058296T2/hu unknown
- 2015-12-23 CN CN202010295176.XA patent/CN111574464A/zh active Pending
- 2015-12-23 EA EA202091115A patent/EA202091115A1/ru unknown
- 2015-12-23 UA UAA201707115A patent/UA117796C2/uk unknown
- 2015-12-23 CA CA2972021A patent/CA2972021C/fr active Active
- 2015-12-23 BR BR102015032361-1A patent/BR102015032361B1/pt active IP Right Grant
- 2015-12-23 MA MA048448A patent/MA48448A/fr unknown
- 2015-12-23 US US14/998,042 patent/US9730936B2/en active Active
- 2015-12-23 ES ES15832711T patent/ES2715507T3/es active Active
- 2015-12-23 KR KR1020197034431A patent/KR102288855B1/ko active IP Right Grant
- 2015-12-23 TR TR2019/03672T patent/TR201903672T4/tr unknown
- 2015-12-23 SI SI201531719T patent/SI3521282T1/sl unknown
- 2015-12-23 MY MYPI2017702362A patent/MY189761A/en unknown
2017
- 2017-06-21 IL IL25305917A patent/IL253059B/en active IP Right Grant
- 2017-06-22 EC ECIEPI201739611A patent/ECSP17039611A/es unknown
- 2017-06-22 CO CONC2017/0006214A patent/CO2017006214A2/es unknown
- 2017-06-22 CL CL2017001675A patent/CL2017001675A1/es unknown
- 2017-06-22 SV SV2017005471A patent/SV2017005471A/es unknown
- 2017-06-22 DO DO2017000151A patent/DOP2017000151A/es unknown
- 2017-06-23 MX MX2019009932A patent/MX2019009932A/es unknown
- 2017-06-23 PH PH12017501191A patent/PH12017501191B1/en unknown
- 2017-06-24 SA SA517381826A patent/SA517381826B1/ar unknown
- 2017-06-27 US US15/634,527 patent/US10206926B2/en active Active
2018
- 2018-03-12 HK HK18103444.6A patent/HK1244001B/zh unknown
- 2018-07-04 JP JP2018127603A patent/JP2018168181A/ja active Pending
2019
- 2019-01-04 US US16/239,578 patent/US10548898B2/en active Active
- 2019-09-25 IL IL269635A patent/IL269635B/en active IP Right Grant
- 2019-12-18 US US16/718,311 patent/US11304948B2/en active Active
2021
- 2021-11-10 CY CY20211100979T patent/CY1124726T1/el unknown
2022
- 2022-03-09 US US17/690,351 patent/US20230043136A1/en active Pending

Also Published As

Publication number	Publication date
WO2016105564A1 (fr)	2016-06-30
BR102015032361B1 (pt)	2021-12-21
TWI699355B (zh)	2020-07-21
JP2018168181A (ja)	2018-11-01
KR20190133068A (ko)	2019-11-29
MX2019009932A (es)	2019-10-02
EP3521282A1 (fr)	2019-08-07
EP3237398A1 (fr)	2017-11-01
PL3237398T3 (pl)	2019-05-31
EA202091115A1 (ru)	2021-01-29
EP3960735C0 (fr)	2023-09-13
SG11201705215PA (en)	2017-07-28
NZ733174A (en)	2018-12-21
US20190134035A1 (en)	2019-05-09
EP3521282B1 (fr)	2021-08-25
US20170354656A1 (en)	2017-12-14
SG10202101143VA (en)	2021-03-30
JP2018500358A (ja)	2018-01-11
CA2972021C (fr)	2020-04-28
HK1244001B (zh)	2020-01-10
US20230043136A1 (en)	2023-02-09
AU2015371198B2 (en)	2018-09-27
WO2016105564A8 (fr)	2016-10-06
US9730936B2 (en)	2017-08-15
BR102015032361A2 (pt)	2016-07-05
US20160250215A1 (en)	2016-09-01
US10548898B2 (en)	2020-02-04
IL253059A0 (en)	2017-08-31
EP3960735A1 (fr)	2022-03-02
EP3960735B1 (fr)	2023-09-13
CN111574464A (zh)	2020-08-25
PE20171306A1 (es)	2017-09-05
SA517381826B1 (ar)	2021-10-21
MX367574B (es)	2019-08-27
SI3237398T1 (sl)	2019-04-30
PH12017501191A1 (en)	2018-03-05
SV2017005471A (es)	2018-01-18
MY189761A (en)	2022-03-03
TR201903672T4 (tr)	2019-04-22
TW201636328A (zh)	2016-10-16
ES2964395T3 (es)	2024-04-05
PL3521282T3 (pl)	2022-01-03
KR102049476B1 (ko)	2019-11-28
MD20170070A2 (ro)	2017-12-31
DK3521282T3 (da)	2021-09-27
CA2972021A1 (fr)	2016-06-30
MX2017008521A (es)	2018-03-01
EA201791256A1 (ru)	2018-04-30
IL269635B (en)	2021-04-29
HUE058296T2 (hu)	2022-07-28
TW202106667A (zh)	2021-02-16
TWI770552B (zh)	2022-07-11
CL2017001675A1 (es)	2018-05-11
US11304948B2 (en)	2022-04-19
CR20170281A (es)	2017-11-08
ES2715507T3 (es)	2019-06-04
ECSP17039611A (es)	2017-07-31
AU2015371198A1 (en)	2017-07-13
US20200360383A1 (en)	2020-11-19
CY1124726T1 (el)	2022-07-22
IL269635A (en)	2019-11-28
PT3521282T (pt)	2021-11-29
JP6367489B2 (ja)	2018-08-01
CU20170089A7 (es)	2017-11-07
CN107278201A (zh)	2017-10-20
TW202237569A (zh)	2022-10-01
EP4302830A2 (fr)	2024-01-10
LT3521282T (lt)	2021-11-25
AR103252A1 (es)	2017-04-26
CO2017006214A2 (es)	2017-10-20
EA035746B1 (ru)	2020-08-05
HRP20211543T1 (hr)	2022-01-07
ES2900810T3 (es)	2022-03-18
MD4650B1 (ro)	2019-09-30
UA117796C2 (uk)	2018-09-25
EP3237398B1 (fr)	2018-12-19
IL253059B (en)	2019-10-31
DOP2017000151A (es)	2017-09-15
BR102015032361A8 (pt)	2021-08-31
PT3237398T (pt)	2019-03-06
KR20170131351A (ko)	2017-11-29
CN107278201B (zh)	2020-05-19
SI3521282T1 (sl)	2021-11-30
PH12017501191B1 (en)	2018-03-05
KR102288855B1 (ko)	2021-08-11
US10206926B2 (en)	2019-02-19
PL3960735T3 (pl)	2024-03-18
EP4302830A3 (fr)	2024-03-13

Publication	Publication Date	Title
MA48448A (fr)	2021-04-28	Dérivés de quinazoline utilisés pour traiter le vih
MA40872A (fr)	2021-05-26	Méthodes pour la préparation de ribosides
MA41449A (fr)	2017-12-12	Polythérapies pour le traitement de cancers
MA41898A (fr)	2018-02-13	Dérivés de quinazolinone bicyclique
MA52906A (fr)	2021-04-21	Procédé de préparation d'amg 416
MA54254A (fr)	2021-09-22	Dérivés de benzodiazépine cytotoxique
IL252311B (en)	2020-07-30	4-oxo-4,3-dihydro-3,2,1-benzotriazines as G protein-coupled receptor modulators 139
HK1257272A1 (zh)	2019-10-18	治療hiv的工具
DK3302478T3 (da)	2022-02-14	Pac-1 kombinations behandling
MA41174A (fr)	2017-10-25	Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
BR112016027819A2 (pt)	2017-08-22	Processo de preparação de derivados de tiazole
FR3021224B1 (fr)	2017-11-17	Phytomedicament pour le vih
KR20180084983A (ko)	2018-07-25	암의 치료를 위한 피리미도-피리미다지논의 용도
MA41641A (fr)	2018-01-09	Dérivés de tétrahydropyranylbenzamide
ITUB20155450A1 (it)	2017-05-11	Composizione per il trattamento delle dermatiti.
TH1401007061B (th)	2016-02-26	ชุดเครื่องบังคับเลี้ยว
FR3023706B1 (fr)	2016-09-02	Orthese de genou
FR3024135B1 (fr)	2017-03-10	Piece de harnachement
AU2014903428A0 (en)	2014-09-11	Treatment of HIV
TH1501006284A (th)	2018-03-16	กระบวนการของการอีพอกซิเดชัน